MX2009008461A - Variantes geneticas que contribuyen a riesgo de cancer de prostata. - Google Patents

Variantes geneticas que contribuyen a riesgo de cancer de prostata.

Info

Publication number
MX2009008461A
MX2009008461A MX2009008461A MX2009008461A MX2009008461A MX 2009008461 A MX2009008461 A MX 2009008461A MX 2009008461 A MX2009008461 A MX 2009008461A MX 2009008461 A MX2009008461 A MX 2009008461A MX 2009008461 A MX2009008461 A MX 2009008461A
Authority
MX
Mexico
Prior art keywords
prostate cancer
risk
genetic variants
susceptibility
determining
Prior art date
Application number
MX2009008461A
Other languages
English (en)
Inventor
Julius Gudmundsson
Patrick Sulem
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of MX2009008461A publication Critical patent/MX2009008461A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se caracteriza por ciertas variantes genéticas que son variantes de susceptibilidad para cáncer de próstata. La invención se refiere a métodos para detectar susceptibilidad incrementada a cáncer de próstata, así como a métodos para determinar susceptibilidad disminuida a cáncer de próstata, usando estas variantes. La invención se refiere adicionalmente a kits para determinar una susceptibilidad a cáncer de próstata.
MX2009008461A 2007-02-07 2008-02-07 Variantes geneticas que contribuyen a riesgo de cancer de prostata. MX2009008461A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8604 2007-02-07
IS8654 2007-06-22
PCT/IS2008/000003 WO2008096375A2 (en) 2007-02-07 2008-02-07 Genetic variants contributing to risk of prostate cancer

Publications (1)

Publication Number Publication Date
MX2009008461A true MX2009008461A (es) 2009-08-17

Family

ID=39650503

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008461A MX2009008461A (es) 2007-02-07 2008-02-07 Variantes geneticas que contribuyen a riesgo de cancer de prostata.

Country Status (13)

Country Link
US (1) US8865400B2 (es)
EP (2) EP2115171B1 (es)
JP (1) JP2010520745A (es)
CN (1) CN102317470A (es)
AU (1) AU2008212117B2 (es)
BR (1) BRPI0807236A2 (es)
CA (1) CA2677994A1 (es)
IL (1) IL200197A (es)
IN (1) IN2009DN05722A (es)
MX (1) MX2009008461A (es)
NZ (1) NZ579401A (es)
SG (1) SG193026A1 (es)
WO (1) WO2008096375A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697360B2 (en) * 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
WO2009085196A1 (en) * 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
WO2011149534A2 (en) 2010-05-25 2011-12-01 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
WO2012029080A1 (en) * 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
CN103060433B (zh) * 2012-10-19 2014-12-03 卫生部北京医院 一种预测前列腺癌易感性的试剂盒和方法
JP2016508026A (ja) * 2012-11-20 2016-03-17 ファディア・アクチボラゲットＰｈａｄｉａ ＡＢ 前立腺癌を有する個体の予後診断方法
WO2017164699A1 (ko) * 2016-03-24 2017-09-28 서울대학교병원 (분사무소) 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
KR101944927B1 (ko) 2016-03-24 2019-02-07 서울대학교산학협력단 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발
KR102068667B1 (ko) * 2019-02-28 2020-01-21 주식회사 프로카젠 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102068666B1 (ko) * 2019-02-28 2020-02-11 주식회사 프로카젠 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371654B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
KR102371655B1 (ko) * 2019-02-28 2022-03-08 주식회사 프로카젠 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체
CN110596060B (zh) * 2019-09-12 2020-08-21 江南大学 一种检测前列腺特异性抗原的光谱分析中荧光传感器的构建方法及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5288611A (en) 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
EP0756010B1 (en) 1983-01-10 2001-07-04 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0562025B1 (en) 1990-12-06 2001-02-07 Affymetrix, Inc. (a Delaware Corporation) Compounds and their use in a binary synthesis strategy
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
DE69527585T2 (de) 1994-06-08 2003-04-03 Affymetrix Inc Verfahren und Vorrichtung zum Verpacken von Chips
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
CA2255774C (en) 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5925519A (en) * 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
CA2328500A1 (en) 1998-06-05 1999-12-16 Genset Polymorphic markers of prostate carcinoma tumor antigen-1 (pcta-1)
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
WO2000027864A1 (en) * 1998-11-06 2000-05-18 Myriad Genetics, Inc. CHROMOSOME 17p-LINKED PROSTATE CANCER SUSCEPTIBILITY GENE
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
WO2004028346A2 (en) 2002-09-25 2004-04-08 Amersham Biosciences (Sv) Corp. Detection methods
US20050136407A1 (en) 2003-12-19 2005-06-23 Cramer Scott D. Genetic polymorphisms in the prostate-specific antigen gene promoter
US20050255507A1 (en) 2004-02-17 2005-11-17 Jenkins Robert B Cytogenetically determined diagnosis and prognosis of proliferative disorders
WO2006063285A2 (en) 2004-12-10 2006-06-15 Sequenom, Inc. Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
US20090317799A1 (en) * 2005-05-18 2009-12-24 Decode Genetics Ehf. Variants at chr8q24.21 confer risk of cancer
WO2008050356A1 (en) * 2006-10-27 2008-05-02 Decode Genetics Cancer susceptibility variants on chr8q24.21
US8697360B2 (en) * 2007-11-30 2014-04-15 Decode Genetics Ehf. Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition

Also Published As

Publication number Publication date
EP2522743A2 (en) 2012-11-14
EP2115171A2 (en) 2009-11-11
BRPI0807236A2 (pt) 2019-09-24
CA2677994A1 (en) 2008-08-14
WO2008096375A3 (en) 2008-12-18
EP2522743A3 (en) 2013-08-07
WO2008096375A2 (en) 2008-08-14
US8865400B2 (en) 2014-10-21
US20100041037A1 (en) 2010-02-18
IL200197A0 (en) 2010-04-29
AU2008212117B2 (en) 2014-09-11
JP2010520745A (ja) 2010-06-17
AU2008212117A1 (en) 2008-08-14
SG193026A1 (en) 2013-09-30
NZ579401A (en) 2012-03-30
EP2115171B1 (en) 2015-01-21
IN2009DN05722A (es) 2015-07-24
CN102317470A (zh) 2012-01-11
IL200197A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
MX2009008461A (es) Variantes geneticas que contribuyen a riesgo de cancer de prostata.
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
HK1143190A1 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
GB2460769A (en) Tle3 as a marker for chemotherapy
MX340453B (es) Biomarcadores para cancer de pulmon.
WO2009134487A3 (en) Optimized methods for delivery of dsrna targeting the pcsk9 gene
MX340181B (es) Plantas de pepino resistentes al mildiu velloso.
EP1864134A4 (en) METHODS OF TREATING OR PREVENTING HORMONE-RESISTANT PROSTATE CANCER USING SMALL INTERFERING RNA SPECIFIC TO PROTOCADHERINE-PC, OR OTHER INHIBITORS OF PROTOCADHERINE-PC EXPRESSION OR ACTIVITY
TR201901930T4 (tr) Topraktaki mikrobiyal aktivitenin geliştirilmesine yönelik bir yöntem.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
MX2011013243A (es) Marcadores de riesgo para enfermedad cardiovascular.
IN2012DN02485A (es)
SG169988A1 (en) Rnai inhibition of alpha-enac expression
EP2516624A4 (en) CELL LINE 3M
MX2011011431A (es) Composicion para el tratamiento de cancer de prostata.
MY156954A (en) PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSES
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
MX2009007695A (es) Compuestos complejos de carbohidrato de hierro.
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
MX339300B (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos.
MX2009006943A (es) Procedimiento para la mejor utilizacion del potencial de produccion de plantas transgenicas.
BRPI0910383A2 (pt) compostos de poliuretano e/ou policarboanto de amônio
WO2012112956A3 (en) Compounds and methods for targeting leukemic stem cells

Legal Events

Date Code Title Description
FG Grant or registration